Kolsum Umme, Ravi Arjun, Hitchen Paul, Maddi Satyanarayana, Southworth Thomas, Singh Dave
Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester and University Hospital of South Manchester NHS Foundation Trust, Manchester, M23 9QZ, UK.
The Medicines Evaluation Unit, Manchester, M23 9QZ, UK.
Respir Res. 2017 Apr 26;18(1):73. doi: 10.1186/s12931-017-0559-0.
Eosinophilic COPD appears to be a distinct patient subgroup with an increased corticosteroid response. Eosinophilic COPD has been labelled as part of the asthma COPD overlap syndrome (ACOS). We compared the clinical characteristics of eosinophilic COPD patients (without any clinical history of asthma) and COPD patients with a childhood history of asthma. COPD patients with asthma were characterised by more allergies and more exacerbations, but less eosinophilic inflammation. While terms such as "ACOS" are used to "lump" patients together, we report distinct differences between eosinophilic COPD and COPD patients with asthma, and propose that these groups should be split rather than lumped.
嗜酸性粒细胞性慢性阻塞性肺疾病（COPD）似乎是一个独特的患者亚组，其对皮质类固醇的反应增强。嗜酸性粒细胞性COPD已被标记为哮喘-COPD重叠综合征（ACOS）的一部分。我们比较了嗜酸性粒细胞性COPD患者（无任何哮喘临床病史）和有儿童哮喘病史的COPD患者的临床特征。患有哮喘的COPD患者的特点是过敏更多、急性加重更多，但嗜酸性粒细胞炎症更少。虽然“ACOS”等术语用于将患者归为一类，但我们报告了嗜酸性粒细胞性COPD和患有哮喘的COPD患者之间的明显差异，并建议应将这些组分开而非合并。
